Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBluecross Idaho Orencia IV Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedBluecross IdahoPolicy N/A

    Orencia (abatacept) for Intravenous Use

    Customize your policy alerts

    Sign up for all Bluecross Idaho policy alerts

    Know when Bluecross Idaho releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage under the medical benefit for intravenous Orencia (abatacept), including initial and continuation authorization criteria, dosing, and investigational uses. Subcutaneous abatacept is managed under the pharmacy benefit.

    Policy Summary
    PayerBluecross Idaho
    PolicyOrencia (abatacept) for Intravenous Use
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 202744d
    Last ReviewSep 24, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for intravenous abatacept before treatment.
    SourceLink
    POLICY UPDATE CHANGES

    A statement regarding National Comprehensive Cancer Network (NCCN) indications was added.

    Criteria related to tuberculosis infections and tuberculosis screening were clarified.

    1 yearPrior-approval duration
    18+

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Adult minimum age
    6+Juvenile minimum age
    J0129Abatacept HCPCS
    4Infusion codes

    Coverage Criteria

    Initial Therapy

    Covered when all of the following requirements are met, including at least one covered indication below.

    ALL of the following

    • ONE of the following

      • Individual has had an inadequate therapeutic response to at least two (2) covered alternative products for the requested indication, when available, under either the pharmacy or medical benefit.
      • Individual has a documented contraindication or intolerance to all available covered alternatives under the pharmacy and medical benefits for the requested indication.

        Pharmacy-covered alternatives apply only to members with Blue Cross of Idaho pharmacy benefits.

    • Abatacept is not being used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator.

      See Appendices.

    • Dosing is initiated in accordance with FDA-approved labeling and/or accepted drug compendia dosing.
    • ONE of the following indications

      • Rheumatoid Arthritis (RA)

        • Individual is 18 years of age or older with moderately to severely active RA.
        • ONE of the following

          • Individual has had an inadequate response to methotrexate titrated to the maximally tolerated dose.
          • If methotrexate is not tolerated or is contraindicated, documentation shows an inadequate response to, intolerance of, or contraindication to another conventional therapy option, such as sulfasalazine, leflunomide, or hydroxychloroquine.

            See Appendices.

      • Polyarticular Juvenile Idiopathic Arthritis (pJIA)

        • Individual is 6 years of age or older with active moderate to severe pJIA.

    Continuation Therapy

    Continuation requests for intravenous abatacept may be considered medically necessary when all of the following are met:

    ALL of the following

    • Coverage criteria for initiation of abatacept therapy for the requested indication have previously been met.
    • There is clinically significant and functionally relevant improvement or stabilization in the clinical signs and symptoms of the disease.
    • Abatacept is not being used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator.

      See Appendices.

    Investigational Uses

    Intravenous abatacept may be considered investigational under any of the following circumstances:

    ONE of the following

    • Abatacept is used in combination with topical or oral JAK inhibitors, ozanimod, etrasimod, apremilast, deucravacitinib, or any of the following biologic immunomodulators: TNF antagonists, IL-23 inhibitors, IL-17 inhibitors, vedolizumab, ustekinumab, IL-1 inhibitors, IL-6 inhibitors, rituximab, or natalizumab.
    • The initial or continuation coverage criteria are not met for any indication other than an oncologic indication.

    Intravenous abatacept is covered under the medical benefit and is subject to this policy. Subcutaneous abatacept is filled under the pharmacy benefit and is subject to associated utilization management requirements and/or formulary coverage designations, such as prior authorization or formulary restrictions. Subcutaneous abatacept is outside the scope of this medical policy.

    Requests for oncologic use of abatacept, including acute and chronic graft-versus-host disease and immune checkpoint inhibitor therapy-related toxicities, are evaluated according to National Comprehensive Cancer Network (NCCN) guidelines. Refer to Blue Cross of Idaho Medical Policy 5.01.501, Guidelines for Prior Authorization of Pharmacologic Therapies, for additional information regarding coverage of oncologic drug use.

    Billing and Coding

    HCPCSHCPCS
    J0129Injection, abatacept, 10 mg when drug is administered under the direct supervision of a physician. (Not for use when drug is self-administered.)
    CPTCPT
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug)
    96366Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug)
    96367Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug)
    96368Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug)
    NDCNDC
    0003-2187-13Orencia 250 mg single-use vial
    ICD-10-CMICD-10
    M05.00-M05.09Rheumatoid arthritis
    M05.320-M06.39Rheumatoid arthritis and related inflammatory polyarthropathies
    M06.80-M06.9Other rheumatoid arthritis and rheumatoid arthritis, unspecified
    M08.00-M08.9Juvenile rheumatoid arthritis / juvenile idiopathic arthritis
    L40.50-L40.59Psoriatic arthritis
    D89.811Chronic graft-versus-host disease
    D89.812Acute graft-versus-host disease
    Place of ServiceRevenue
    Outpatient, physician officePlace of service listed for the service

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for intravenous abatacept (Orencia) to ensure safe, clinically appropriate, and cost-effective use. Subcutaneous abatacept is outside this medical policy and is subject to pharmacy-benefit requirements.

    Step Therapy

    Covered-Alternative Prerequisite

    Before initial intravenous abatacept therapy, document an inadequate therapeutic response to at least two covered alternative products for the requested indication, when available, across the pharmacy or medical benefit. Alternatively, document a contraindication or intolerance to all available covered alternatives; pharmacy alternatives apply only to members with Blue Cross of Idaho pharmacy benefits.

    • Covered alternatives may be under the pharmacy or medical benefit.
    • Pharmacy-benefit alternatives apply only when the member has Blue Cross of Idaho pharmacy benefits.

    Unsupported block type: documentation保

    Clinical Background

    Abatacept is a selective T-cell co-stimulation modulator. It binds to CD80 and CD86 and blocks their interaction with CD28, inhibiting the co-stimulatory signal required for full T-cell activation. Because activated T cells contribute to rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriatic arthritis, abatacept may be used in the management of these inflammatory conditions.

    Definitions and Indication Terms

    Acute graft-versus-host disease prophylaxis
    Policy-history indicationAcute graft-versus-host disease (aGVHD) prophylaxis is identified as an indication for intravenous Orencia (abatacept) when medical criteria are met.
    Related codeICD-10-CM D89.812 — Acute graft-versus-host disease (aGVHD).
    Policy contextThe policy history lists aGVHD prophylaxis among the indications for intravenous Orencia alongside rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriatic arthritis.

    Initial Intravenous Abatacept

    Initial Intravenous Abatacept

    Initial intravenous abatacept may be considered medically necessary when all prerequisites and one indication-specific branch below are satisfied.

    Initial intravenous abatacept prerequisites and indication

    • Alternative-treatment prerequisite: The individual has had an inadequate therapeutic response to at least two covered alternative products for the requested indication, if available, on either the pharmacy or medical benefit; or has a documented contraindication or intolerance to all available covered alternatives on the pharmacy and medical benefit for the requested indication.At least 2 covered alternatives when available

      Pharmacy covered alternatives apply only to members with Blue Cross of Idaho pharmacy benefits.

    • Safety and dosing prerequisites: Abatacept is not being used in combination with another biologic DMARD, targeted synthetic DMARD, or other immunomodulator, and dosing is initiated in accordance with FDA-approved labeling and/or accepted drug compendia dosing.

    Continuation of Intravenous Abatacept

    Continuation of Intravenous Abatacept

    Continuation requests for intravenous abatacept may be considered medically necessary when all of the following requirements are met.

    Ongoing authorization requirements: Initial coverage criteria for the requested indication were previously met; there is clinically significant and functionally relevant improvement or stabilization in disease signs and symptoms; and abatacept is not being used with another biologic DMARD, targeted synthetic DMARD, or other immunomodulator.

    Covered Alternative Therapy

    StepRequirementFailure or exception
    1Before initial intravenous abatacept authorization, trial at least two covered alternative products for the requested indication when available, using alternatives covered under the pharmacy or medical benefit.The individual must have an inadequate therapeutic response to at least two covered alternatives, or a documented contraindication or intolerance to all available covered alternatives. Pharmacy alternatives apply only to members with Blue Cross of Idaho pharmacy benefits.

    Authorization Duration and Quantity Parameters

    Prior approval duration
    MedicationIntravenous abatacept (Orencia).
    Prior approval durationUp to 1 year.
    Applies toEach course of intravenous abatacept treatment.

    Administration Site

    Billing Rule

    Use the listed office site of care

    The coding section lists intravenous abatacept services in an outpatient physician office place of service. Submit the service under the appropriate outpatient physician office setting.

    Policy Summary
    PayerBluecross Idaho
    PolicyOrencia (abatacept) for Intravenous Use
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 202744d
    Last ReviewSep 24, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for intravenous abatacept before treatment.
    SourceLink
    On This Page
    Coverage CriteriaBilling and CodingAuthorization and Documentation RequirementsClinical BackgroundDefinitions and Indication TermsInitial Intravenous AbataceptContinuation of Intravenous AbataceptCovered Alternative TherapyAuthorization Duration and Quantity ParametersAdministration Site
  1. Individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy, such as DMARDs including methotrexate, sulfasalazine, cyclosporine, or leflunomide.

    See Appendices.

  2. Psoriatic Arthritis (PsA)

    • Individual is 18 years of age or older with active moderate to severe psoriatic arthritis.
    • Individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy, such as DMARDs including methotrexate, sulfasalazine, cyclosporine, or leflunomide.

      See Appendices.

  3. Documentation Required

    Indication-Specific Clinical Documentation

    Submit indication-specific clinical documentation supporting the diagnosis, age, disease activity, and prior conventional-therapy history. Covered indications include rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (pJIA), and psoriatic arthritis (PsA); oncologic uses are evaluated under NCCN guidelines.

    • RA: age 18 or older, moderately to severely active disease, and inadequate response to maximally tolerated methotrexate; if methotrexate is not tolerated or contraindicated, document inadequate response, intolerance, or contraindication to sulfasalazine, leflunomide, or hydroxychloroquine.
    • pJIA: age 6 or older with active moderate to severe disease and inadequate response, intolerance, or contraindication to conventional DMARD therapy such as methotrexate, sulfasalazine, cyclosporine, or leflunomide.
    • PsA: age 18 or older with active moderate to severe disease and inadequate response, intolerance, or contraindication to conventional DMARD therapy such as methotrexate, sulfasalazine, cyclosporine, or leflunomide.
    Documentation Required

    Continuation Response Documentation

    For continuation requests, document that the initial abatacept criteria for the requested indication were previously met and that treatment has produced clinically significant, functionally relevant improvement or stabilization in disease signs and symptoms.

    • Continuation also requires confirmation that abatacept is not being used with another biologic DMARD, targeted synthetic DMARD, or other immunomodulator.
    Billing Rule

    Combination and Dosing Verification

    Verify before treatment that abatacept is not being combined with prohibited immunomodulatory therapy and that dosing is initiated according to FDA-approved labeling and/or accepted drug compendia dosing.

    • Confirm the requested regimen and dose comply with FDA-approved labeling or accepted compendia dosing.
    • Review the complete medication list for prohibited combination therapy.
    Denial Risk

    Prohibited Combination Therapy

    Do not use intravenous abatacept in combination with another biologic DMARD, targeted synthetic DMARD, or other immunomodulator. Such combinations include the specified JAK inhibitors and biologic immunomodulators below.

    • Topical or oral JAK inhibitors, ozanimod, etrasimod, apremilast, and deucravacitinib.
    • TNF antagonists, IL-23 inhibitors, IL-17 inhibitors, vedolizumab, ustekinumab, IL-1 inhibitors, IL-6 inhibitors, rituximab, or natalizumab.
    Denial Risk

    Unmet Criteria or Unsupported Indication

    Requests that do not meet the applicable initiation or continuation criteria, or that are submitted for unsupported indications, may be denied or considered investigational. This includes all other indications not supported by the policy, excluding oncologic indications evaluated under NCCN guidelines.

    • Combination therapy with the prohibited agents listed in this policy is considered investigational.
    • Continuation requires clinically significant and functionally relevant improvement or stabilization.
    Denial Risk

    Insufficient Alternative-Treatment History

    Initial therapy cannot be approved without sufficient alternative-treatment history. If fewer than two covered alternatives were tried, the record must explain the documented contraindication or intolerance to all available covered alternatives; otherwise, the request may be denied.

    • Include treatment names, outcomes, dates or duration when available, and the specific reason an alternative was ineffective, contraindicated, or not tolerated.
  4. Indication-specific medical necessity

    • Rheumatoid arthritis: The individual is 18 years of age or older with moderately to severely active rheumatoid arthritis and has had an inadequate response to methotrexate titrated to the maximally tolerated dose; or, if methotrexate is not tolerated or is contraindicated, documentation shows inadequate response to, intolerance of, or contraindication to sulfasalazine, leflunomide, or hydroxychloroquine.Age 18 or older
    • Polyarticular juvenile idiopathic arthritis: The individual is 6 years of age or older with active moderate to severe polyarticular juvenile idiopathic arthritis and has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy such as methotrexate, sulfasalazine, cyclosporine, or leflunomide.Age 6 or older
    • Psoriatic arthritis: The individual is 18 years of age or older with active moderate to severe psoriatic arthritis and has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy such as methotrexate, sulfasalazine, cyclosporine, or leflunomide.Age 18 or older